BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXSep 8, 2016, 8:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
BusinessOncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016By Nasdaq OMXApr 19, 2016, 1:00 PM UTC
BusinessOncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016By Nasdaq OMXMar 16, 2016, 8:30 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing FacilityBy Nasdaq OMXMar 7, 2016, 1:05 PM UTC
